Afficher la couverture 'Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Mazieres, J.' en grand format
/5

0 avis

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Archive ouverte

Mazieres, J. | Drilon, A. | Lusque, A. | Mhanna, L. | Cortot, A.B. | Mezquita, L. | Thai, A.A. | Mascaux, C. | Couraud, S. | Veillon, R. | van den Heuvel, M. | Neal, J. | Peled, N. | Früh, M. | Ng, T.L. | Gounant, V. | Popat, S. | Diebold, J. | Sabari, J. | Zhu, V.W. | Rothschild, S.I. | Bironzo, P. | Martinez-Marti, A. | Curioni-Fontecedro, A. | Rosell, R. | Lattuca-Truc, M. | Wiesweg, M. | Besse, B. | Solomon, B. | Barlesi, F. | Schouten, R.D. | Wakelee, H. | Camidge, D.R. | Zalcman, G. | Novello, S. | Ou, S.I. | Milia, J. | Gautschi, O.

Edité par CCSD ; Elsevier -

International audience. Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.

Consulter en ligne

Suggestions

Du même auteur

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Archive ouverte | Mazières, J. | CCSD

International audience

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Archive ouverte | Peters, S. | CCSD

International audience

Caractéristiques et prise en charge de l’évolutivité cérébro-méningée des cancers bronchiques dans un contexte de mutation activatrice

Archive ouverte | Rouviere, D. | CCSD

International audience

Chargement des enrichissements...